Clomiphene
Clomid
Clomiphene (Clomid) is a hormonal & sexual research compound. SERM — blocks estrogen receptors at the hypothalamus, raising LH/FSH to restart natural testosterone.
Clomiphene quick facts
| Reported research dose | 12.5mg-50mg |
| Route | Oral |
| Frequency | 1x Daily |
| Half-life | ~5-7 days |
| Forms | Oral |
| Evidence level | Human (established) |
The classic testosterone-restart SERM. Enclomiphene is its cleaner isomer without the mood-heavy zuclomiphene.
How Clomiphene works
SERM — blocks estrogen receptors at the hypothalamus, raising LH/FSH to restart natural testosterone.
Proposed benefits
Researched for libido, hormonal signaling and reproductive / sexual function.
Where to get Clomiphene
Buy Clomiphene at AlgoRx →The evidence for Clomiphene
Graded by what exists behind each claim.
✅ Clinically validated
- Decades of approved human use for ovulation induction in women, with extensive trial data. Off-label use for male hypogonadism has published clinical series showing reliable testosterone elevation with preserved fertility.
📊 Correlative data
- Long-standing use in male fertility and TRT-alternative practice. The reported experience is that it works, and that a meaningful minority discontinue for mood changes or visual disturbance.
🧪 Theoretical / extrapolated
- A SERM that blocks estrogen feedback at the pituitary, so the brain reads estrogen as low and raises LH and FSH.
- The mixture is the mechanistic problem — see enclomiphene. The zuclomiphene isomer has a half-life of weeks and accumulates, which is the best explanation for the side effects and the reason the isolated isomer was developed.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Clomiphene actually does
Clomiphene is not a molecule. It is a ratio, and the ratio changes while you take it. The FDA label says so in its own description: CLOMID “is a mixture of two geometric isomers [cis (zuclomiphene) and trans (enclomiphene)] containing between 30% and 50% of the cis-isomer” U.S. Food and Drug Administration 2012. Every other statement on this page follows from that sentence, and almost nothing written about clomiphene for men acknowledges it.
What the trans isomer does. Enclomiphene is a competitive antagonist at the estrogen receptor in the hypothalamus. Estradiol is the dominant negative-feedback signal on GnRH pulse generation in a male — not testosterone — so occupying that receptor with something that binds and does not signal removes the brake. GnRH pulse frequency rises, the pituitary releases more LH and FSH, the Leydig cell makes more testosterone and the Sertoli cell keeps spermatogenesis running. That is the entire therapeutic idea, and it is a restoration of the axis rather than a replacement of its output.
What the cis isomer does, and why it is the interesting half. Zuclomiphene is the slower, more estrogenic, longer-lived isomer. It is not a passenger. Fontenot 2016 dosed male mice by oral gavage for a chronic period with the two isomers separated — enclomiphene at 4 and 40 mg/kg/day, zuclomiphene at 4 and 40 mg/kg/day, against placebo — and reported profound effects on Leydig cells, epididymis, seminal vesicles and kidneys, plus changes in serum testosterone, FSH and LH, associated with zuclomiphene treatment only. The isolated enclomiphene arm had positive effects on testosterone production and no effects on testicular histology. Same drug, split in half, and one half did all the damage.
And here is the fact that makes clomiphene a different drug at week 6 than at day 1. Helo 2017 measured both isomers in the serum of 15 men who had been taking clomiphene citrate 25 mg daily for at least six weeks. Median enclomiphene was 2.2 ng/mL. Median zuclomiphene was 44.0 ng/mL. The median zuclomiphene-to-enclomiphene ratio was 20:1. Age, BMI, duration of treatment and serum testosterone predicted none of it on linear regression. So a man swallowing a tablet that is at most half cis-isomer is, six weeks later, carrying twenty parts of the isomer that damaged mouse reproductive tissue for every one part of the isomer he is taking it for. Nothing on a clomiphene page anywhere states that number, and it is the single most important pharmacological fact about the drug.
The chemistry behind the accumulation is ordinary and that is why it is reliable: two geometric isomers about the same double bond present different faces to the same metabolizing enzymes and to the same transporters, so they clear at different rates, and a difference in clearance rate becomes a difference in steady-state concentration the moment dosing repeats. Give it once and the label's 30–50% is roughly what circulates. Give it daily for six weeks and the slow isomer wins by a factor of twenty.
Cell, rodent, human — and where it stops
Step one, and it is the step that owns the label. Clomiphene is approved for the treatment of ovulatory dysfunction in women desiring pregnancy, starting at 50 mg daily for 5 days U.S. Food and Drug Administration 2012. Every efficacy number, every adverse-reaction percentage and every warning on that label was generated in women taking it for five days at a time to induce ovulation. Of the reported pregnancies, the incidence of multiple pregnancy was 7.98% — 6.9% twin, 0.5% triplet, 0.3% quadruplet, 0.1% quintuplet. That is the drug the FDA reviewed.
Step two, the isomers in animals. Fontenot 2016, in male mice by oral gavage at 4 and 40 mg/kg/day of each separated isomer, found the injury confined to the zuclomiphene arms and concluded that the result “justifies the case for a monoisomeric preparation”. Note the species and the route: mouse, gavage, and 40 mg/kg/day is a dose no man takes. It is a toxicology signal about which isomer carries the risk, not an estimate of how much risk a 25 mg tablet carries.
Step three, the isomers in men, which is where this becomes real. Helo 2017 enrolled 15 men on 25 mg daily for secondary hypogonadism, median age 36 years (range 22–70), median BMI 32.0 kg/m², median treatment duration 25.9 months (range 1.7–86.6). Median total testosterone went from 205.0 to 488.0 ng/dL, estradiol from 17.0 to 34.0 pg/mL and LH from 4.0 to 6.1 mIU/mL, all P < 0.001. Read those three numbers together: testosterone roughly doubled and estradiol also roughly doubled. Clomiphene does not lower estrogen in a man. It raises the substrate that feeds aromatase and the product rises with it.
Step four, the pooled evidence. Hohl 2025 is a systematic review and meta-analysis of randomized controlled trials of clomiphene or enclomiphene in male hypogonadism — the first attempt to put a pooled number on a use that has been routine for twenty years. That such a review was published in 2025 rather than 2005 tells you how thin the randomized record is.
The obstacles, and they are specific. (1) There is no hard-endpoint trial of clomiphene in men. Not fracture, not cardiovascular events, not mortality, not fertility outcomes at scale. The male literature is hormone concentrations and semen parameters in small cohorts. (2) The label's entire safety database is women taking the drug for five days per cycle; the men on this site take it daily for months, and Helo 2017's cohort had a median exposure of over two years. Nobody has ever built a safety denominator for that. (3) The exposure a man actually accumulates is mostly the isomer the trial evidence is not about, at 20:1, and no dose adjustment anywhere accounts for it. (4) Every response number is a group median; Helo 2017 could not predict an individual's isomer concentrations from age, BMI, duration or testosterone, which means there is currently no way to know who is accumulating what.
Clomiphene pharmacokinetics — how much of it actually gets in
Route: oral. And the elimination is the strangest thing on this page. The label states clomiphene citrate is “readily absorbed orally in humans and excreted principally in the feces”, that zuclomiphene has a longer half-life than enclomiphene, that detectable levels of zuclomiphene persisted for longer than a month, and that some radiolabel was still present in the feces 6 weeks after administration U.S. Food and Drug Administration 2012. Fecal excretion of a small lipophilic molecule at that timescale means enterohepatic recirculation: conjugated in the liver, secreted in bile, deconjugated by gut bacteria, reabsorbed.
The primary pharmacokinetic study, and what it did and did not show. Mikkelson 1986 gave a single 50 mg dose to 24 healthy adult female volunteers in a randomized three-phase double-blind crossover comparing three formulations, measuring both isomers and principal metabolites. The Z (cis) isomer peaked later than the E (trans) isomer and was eliminated much more slowly, with significant plasma concentrations still detectable up to 1 month after a single tablet. The three formulations were bioequivalent. Two things about that study matter here: the subjects were women, and it was a single dose. Neither the accumulation a daily user experiences nor the male hormonal response was in scope.
The number on this site's own card needs qualifying. The card gives a half-life of about 5–7 days. The label prints no numeric half-life for clomiphene citrate at all; what it prints is a comparison between the isomers and a persistence of over a month U.S. Food and Drug Administration 2012, and Mikkelson 1986 measured that persistence directly. A single figure cannot describe a two-isomer mixture whose components differ by roughly an order of magnitude in clearance. The honest version is: the isomer you want is short, the isomer you accumulate is long, and after six weeks of daily dosing the long one outnumbers the short one 20 to 1 Helo 2017.
What that implies for stopping. If zuclomiphene is still measurable a month after one tablet, then stopping a months-long course does not produce a clean washout — it produces a slow decline of the estrogenic isomer over weeks while the antagonist isomer disappears in days. Anyone who has felt worse in the two to four weeks after stopping clomiphene has a mechanistic candidate for it, and nobody has measured it.
What would have to be true, and how you would know it was not
Five predictions, each with a marker, a direction and a window. The fourth is the one that cuts against the drug and the fifth is the one nobody tests.
1. LH & FSH and Total Testosterone rise, and LH moves first. Draw LH & FSH and Total Testosterone at baseline and at 6 weeks — six rather than four, because six weeks is the exposure at which Helo 2017 measured its cohort. The published movement is total testosterone from a median 205 to 488 ng/dL and LH from 4.0 to 6.1 mIU/mL, P < 0.001 for both. If LH has not moved at six weeks, the hypothalamic block is not producing an axis response and no amount of additional time will fix it.
2. Estradiol rises, and that is the drug working rather than failing. Order Estradiol, Sensitive (LC/MS-MS), not the immunoassay. Helo 2017 found estradiol roughly doubling alongside testosterone, which is arithmetic: more testosterone is more aromatase substrate. Reaching for an aromatase inhibitor because estradiol went up is the most common error made on this drug — the receptor clomiphene is blocking is the one that matters for feedback, and crushing estradiol on top of it removes the signal that keeps bone and lipids where they should be.
3. SHBG should rise and free testosterone should lag total. Hepatic estrogen signaling is the main driver of SHBG production, and zuclomiphene is the estrogenic isomer that accumulates 20-fold Helo 2017. So the specific, cheap, falsifiable pattern to look for is a good-looking Total Testosterone sitting above an unimpressive Free Testosterone, with SHBG explaining the gap. This is reasoned from the isomer's known pharmacology rather than measured on this drug in men, and it is labeled as extrapolation for that reason.
4. The prediction that cuts against it: symptoms should get worse late, not early. If the estrogenic isomer takes weeks to reach steady state U.S. Food and Drug Administration 2012 Mikkelson 1986, then mood flattening, water retention and visual symptoms should be a week-four-onward phenomenon rather than a first-week one, and should persist for weeks after stopping. Anybody who tolerates clomiphene beautifully for ten days and concludes they are a responder has measured the wrong isomer at the wrong time. If instead the side-effect profile is front-loaded and settles, the accumulation model is wrong and that would be worth knowing.
5. Visual symptoms, and they are the stop sign. The label reports visual symptoms in 1.5% of patients in clinical trials U.S. Food and Drug Administration 2012, and Purvin 1995 is a dedicated ophthalmology report on visual disturbance secondary to clomiphene citrate. There is no blood marker for this. The read-out is the symptom — blurring, spots, scintillating scotomata — and the correct response is to stop, not to monitor.
What nobody has tested yet
Nobody has related the zuclomiphene concentration to the side effects. Helo 2017 measured the isomers in 15 men and measured hormones in the same men, but no study has ever asked whether the men with the highest zuclomiphene are the men with the mood change, the visual symptoms or the water retention. The assay exists, the cohort would be trivial to assemble from any men's-health clinic, and the answer would immediately tell you whether the fix for clomiphene intolerance is a lower dose, an alternate-day schedule, or the monoisomeric drug.
Nobody has published a washout curve in men. The label's persistence data — over a month for zuclomiphene, radiolabel in the feces at 6 weeks — is from single-dose radiolabel work U.S. Food and Drug Administration 2012, and Mikkelson 1986 is a single dose in women. What happens to the isomer ratio in the eight weeks after a man stops a two-year course has never been measured, which means nobody can say how long after stopping the axis is still being manipulated.
Nobody has run the dose-response that matters. The male dose range in circulation is 12.5 to 50 mg, lifted from a female ovulation-induction label written around 50 mg for five days U.S. Food and Drug Administration 2012. Whether 12.5 mg daily produces the same LH response as 50 mg with a quarter of the zuclomiphene accumulation is the single most practically useful experiment available on this compound, and it requires nothing more exotic than the assay Helo 2017 already used.
Nobody has looked at bone. Clomiphene is used in men for months to years, it modulates the estrogen receptor, and estrogen is the dominant regulator of male bone density. A DEXA arm on any of the existing cohorts would have cost almost nothing and does not exist in the randomized record summarized by Hohl 2025.
Clomiphene — its own safety story, not its class's
The label's headline warning is one a man cannot have, and saying so plainly is more useful than repeating it. The dominant warning on the clomiphene label is ovarian hyperstimulation syndrome, which the label describes as able to progress within 24 hours to several days into gross ovarian enlargement, ascites, dyspnea, oliguria and pleural effusion, with death due to hypovolemic shock, hemoconcentration or thromboembolism U.S. Food and Drug Administration 2012. A male body has no ovary and cannot develop OHSS. That warning is load-bearing for the approved indication and irrelevant here, and a page that copies it across without saying so is padding rather than informing.
What does transfer is the eye. Visual symptoms occurred in 1.5% of patients in the label's clinical trials, described as blurring, spots or flashes and scintillating scotomata; the label states they are usually reversible but that cases of prolonged visual disturbance have been reported and may be irreversible U.S. Food and Drug Administration 2012, and Purvin 1995 is the ophthalmology literature on exactly that. There is no reason the retina and optic pathway of a man should be protected. This is the one adverse effect on the page with a permanent version, it has a 1-in-67 incidence in the approval database, and the correct response to it is discontinuation.
The rest of the label's adverse-reaction table, in the denominator it came from. Ovarian enlargement 13.6%, vasomotor flushes 10.4%, abdominal-pelvic discomfort or bloating 5.5%, nausea and vomiting 2.2%, breast discomfort 2.1%, visual symptoms 1.5%, headache 1.3% U.S. Food and Drug Administration 2012. Two of those — the flushes at 10.4% and the breast discomfort at 2.1% — are estrogen-receptor effects with no sex-specific anatomy behind them, so they are the ones most likely to appear in a man at something like the same rate.
The specific risk this drug has and its monoisomeric sibling does not. Zuclomiphene is the accumulating isomer, it reaches a 20:1 excess over enclomiphene after six weeks of daily dosing Helo 2017, and separated zuclomiphene is the isomer that produced damage to Leydig cells, epididymis, seminal vesicles and kidneys in male mice while separated enclomiphene did not Fontenot 2016. The mouse doses were far above human ones and the species is a mouse, so this is a mechanism-level warning and not a rate. But it is the reason the people who developed the isolated isomer said a monoisomeric preparation was justified, and it is the honest reason to prefer enclomiphene if the choice exists.
And a warning about the partner, because it is real and asymmetric. If a couple are both using clomiphene — which happens, because it is the same drug — the female side carries a 7.98% multiple-pregnancy rate U.S. Food and Drug Administration 2012 and the OHSS warning above. That is a serious, quantified, label-level risk sitting one shared prescription away from a page most people read for the male use.
Sources read for this page
- U.S. Food and Drug Administration. CLOMID (clomiphene citrate) tablets USP - full prescribing information (NDA 016131).. FDA approved labeling, revision 2012
- Mikkelson TJ, Kroboth PD, Cameron WJ, Dittert LW, Chungi V, Manberg PJ. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers.. Fertil Steril 1986 · PMID 3091405
- Purvin VA. Visual disturbance secondary to clomiphene citrate.. Arch Ophthalmol 1995 · PMID 7710399
- Helo S, Mahon J, Ellen J, Wiehle R, Fontenot G, Hsu K, Feustel P, Welliver C, McCullough A. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment.. BJU Int 2017 · PMID 27511863
- Fontenot GK, Wiehle RD, Podolski JS. Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice.. BJU Int 2016 · PMID 26220499
- Hohl A, Chavez MP, Pasqualotto E, Ferreira ROM, Sande-Lee SV, Ronsoni MF. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials.. Arch Endocrinol Metab 2025 · PMID 41066380
Clomiphene — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- Two different mechanisms with one shared consequence: less estrogen signaling. Aromatase inhibitors (anastrozole, exemestane) stop testosterone converting to estradiol; SERMs (tamoxifen, raloxifene, clomiphene, enclomiphene) block or activate the receptor depending on the tissue.
- The predicted harm is the same either way and it is not the one people expect. Estrogen is not a side effect to be eliminated — it is required for bone density, joint comfort, lipid handling, libido and mood in men as well as women. Crushing it produces aching joints, flat libido, low mood and, over years, measurable bone loss.
- Clomiphene specifically is a mixture of two isomers and the longer-lived one (zuclomiphene) accumulates; the visual disturbances reported on it are attributed to that accumulation. Enclomiphene is the isolated isomer, which is the entire argument for it.
What has actually been reported
- Well documented in oncology use: hot flushes, joint pain and reduced bone mineral density on AIs; venous thromboembolism and endometrial changes on tamoxifen.
- Visual disturbance on clomiphene is uncommon but real and is a reason to stop rather than push through.
How to reduce the risk
Same mechanism as the prediction.
- The dose almost everyone gets wrong is the AI dose. These are used in oncology to drive estradiol as close to zero as possible; that is a cancer-treatment goal and it is the wrong target for anyone else. Most people feeling terrible on a protocol are over-suppressing estradiol.
- Measure before adjusting, and measure with the sensitive (LC-MS/MS) estradiol assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
- If an AI is genuinely needed, the lowest effective dose intermittently beats a fixed daily one. Bone density is worth tracking on anything run for more than a year.
What it does to your bloodwork
A fact about the assay.
- Sensitive estradiol, total and free testosterone, LH and FSH, a lipid panel, and — for long-term use — a DEXA for bone density.
Don't run this if
- You are only using one because of a number rather than a symptom. An estradiol reading with no symptoms attached is not a reason to medicate.
The honest unknown
- Long-term outcomes of AI use in otherwise healthy men, at the doses used outside oncology, have not been studied. The bone and lipid consequences are extrapolated from populations taking them for a different reason.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Clomiphene — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Clomiphene moves on your bloodwork
Expected direction, not a measured one.
- Complete Blood Count (CBC) with Differential — ↑ expected to rise
Hematocrit and hemoglobin rise — androgens stimulate erythropoiesis. This is the most reliably predictable movement of any compound in the Vault.
What to do: This is the number that decides whether you keep going. Baseline and every 3 months. Dehydration on the draw day inflates it, so hydrate normally or you will chase a false reading. - Total Testosterone — ↑ expected to rise
Expected. Trough vs peak matters enormously — the same protocol reads completely differently depending on when you drew.
What to do: Draw at the same point in the cycle every time or the trend is noise. - LH & FSH — ↓ expected to fall
Suppressed by negative feedback. This is the mechanism, not a side effect — and it is why exogenous androgen shuts down your own production.
What to do: Relevant if fertility matters to you. Worth knowing before, not after. - Estradiol, Sensitive (LC/MS-MS) — ↑ expected to rise
Aromatization converts a fraction to estradiol, and it rises with the androgen. Use the sensitive (LC-MS/MS) assay — the standard immunoassay is unreliable in men and produces numbers people then medicate.
What to do: If you are reading estradiol in a man, the assay choice matters more than the result. - SHBG (Sex Hormone-Binding Globulin) — ↓ expected to fall
Falls with androgen exposure, which raises the free fraction — so free testosterone can climb faster than total.
What to do: Read total and SHBG together; total alone understates what changed. - Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) — ↓ expected to worsen
HDL falls, sometimes markedly. Oral 17-alpha-alkylated compounds do this far more aggressively than injectable esters.
What to do: Baseline and 12 weeks. ApoB is the better long-term read than LDL-C. - PSA (Total + Free + % Free) — ↑ expected to rise
Androgens can raise PSA modestly. It does not create prostate cancer that wasn't there, but it can unmask it.
What to do: Baseline before starting matters — without it, a later number has nothing to be compared against.
- How to work up to it, and when not to
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Clomiphene in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Clomiphene
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| LH & FSH | Clomiphene works by raising these — this is the mechanism check |
| Total Testosterone | The outcome |
| Estradiol, Sensitive (LC/MS-MS) | Rises alongside, and drives most of the side effects people report |
| SHBG (Sex Hormone-Binding Globulin) | Rises on SERMs, blunting the usable gain |
The Post-Cycle / Recovery & Fertility panel covers these in one order — 9 markers, $184.50 with the discount applied.
Check results you already have → · All 103 markers A–Z
Clomiphene — frequently asked questions
What is Clomiphene?
Clomiphene (Clomid) is a hormonal & sexual research compound. SERM — blocks estrogen receptors at the hypothalamus, raising LH/FSH to restart natural testosterone.
Is the full Clomiphene protocol on this page?
The reported research dose is on this page, along with how Clomiphene works and the evidence behind it. The protocol — how to work up to it, frequency, cycle length, time off, what not to stack it with and Coach Cam's notes — is inside Skool.
What is the half-life of Clomiphene?
Clomiphene has an approximate half-life of ~5-7 days, which is part of what determines how often it's dosed.
What's the evidence behind Clomiphene?
Current evidence level: Human (established). Clomiphene is offered for research purposes only and is not an approved medicine.
Clomiphene inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Clomiphene is used for
Clomiphene appears under 2 goals in the goal router.
Related Hormonal & Sexual compounds
Where this goes next
Clomiphene is the recovery arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.